GO:0036017 response to erythropoietin: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036017 (response to erythropoietin) describes any cellular or organismal change triggered by erythropoietin, a glycoprotein hormone that controls erythropoiesis.
• Erythropoietin response is clinically central to predicting and optimizing treatment of anemia in cancer and myelodysplastic syndromes [1,6,8].
• The COMMANDS trial showed luspatercept versus epoetin alfa in ESA-naive, transfusion-dependent lower-risk MDS, redefining response endpoints [2,3,4].
• Response to erythropoietin involves receptor binding, JAK2/STAT5 signaling, erythroid gene expression, and survival/proliferation of erythroid progenitors [5,7].
• Predictive biomarkers of erythropoietin response include serum erythropoietin levels, transfusion burden, and iron status [1,6,8].
• CRISPR knockout, knock-in, point mutation, and overexpression models enable causal dissection of erythropoietin response genes.
Description
Response to erythropoietin (GO:0036017) is the biological process by which a cell or organism changes its state or activity in reaction to erythropoietin, a glycoprotein hormone that controls erythropoiesis. This process is fundamental to red blood cell production and is a major therapeutic target in anemias of cancer, chronic kidney disease, and myelodysplastic syndromes (MDS) [1,6,8]. Understanding the molecular and cellular events that constitute response to erythropoietin is essential for predicting which patients will benefit from erythropoiesis-stimulating agents (ESAs) and for developing next-generation agents [1,2,3,4,6,8]. Clinically, response to erythropoietin is assessed by hemoglobin improvement, transfusion independence, and erythroid progenitor expansion [1,6,8]. The COMMANDS trial demonstrated that luspatercept can outperform epoetin alfa in ESA-naive, transfusion-dependent lower-risk MDS, highlighting the need to define response mechanisms precisely [2,3,4]. In cancer patients, baseline serum erythropoietin and transfusion burden are used to predict hematopoietic response to recombinant human erythropoietin [6,8]. In MDS, prolonged responses to recombinant human erythropoietin have been observed in a subset of patients, underscoring inter-patient heterogeneity. For researchers, GO:0036017 provides a structured framework to study signaling, transcriptional, and metabolic changes downstream of erythropoietin. It connects receptor-proximal events to erythroid differentiation, survival, and proliferation [5,7]. This article reviews the definition, mechanisms, key genes, disease links, and CRISPR-based methods for interrogating response to erythropoietin.
response to erythropoietin At A Glance
| GO ID | GO:0036017 |
|---|---|
| GO term | response to erythropoietin |
| Ontology | biological_process |
| Synonym | none |
| Major function | Mediates cellular and organismal changes triggered by erythropoietin, including erythroid proliferation, survival, and differentiation [1,5,7] |
| Stimulus | Erythropoietin, a glycoprotein hormone that controls erythropoiesis |
| Clinical relevance | Predicts and optimizes response to ESA therapy in cancer and MDS [1,6,8] |
| Therapeutic context | Luspatercept versus epoetin alfa in lower-risk MDS (COMMANDS trial) [2,3,4] |
| Key signaling | Erythropoietin receptor, JAK2/STAT5, MAPK, PI3K/AKT pathways [5,7] |
What Is GO:0036017?
GO:0036017 (response to erythropoietin) is defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an erythropoietin stimulus. Erythropoietin is a glycoprotein hormone that controls erythropoiesis. In practice, this term captures the full cascade from erythropoietin receptor engagement through downstream signaling, transcriptional reprogramming, and functional erythroid outcomes [1,5,7].
Why Is response to erythropoietin Important in Cell Biology?
Response to erythropoietin is clinically important because it determines the efficacy of erythropoiesis-stimulating agents in anemia of cancer, chronic kidney disease, and myelodysplastic syndromes [1,6,8]. Predicting response can optimize outcomes and avoid unnecessary exposure to ineffective or toxic treatments [1,6,8]. The COMMANDS trial established luspatercept as a potential first-line alternative to epoetin alfa in ESA-naive, transfusion-dependent lower-risk MDS, making precise understanding of erythropoietin response mechanisms even more critical [2,3,4]. In addition, erythropoietin signaling has been implicated in non-hematopoietic contexts such as glaucoma, expanding the biological scope of GO:0036017.
• Defines the molecular basis of erythroid progenitor proliferation and survival in response to erythropoietin [1,5,7].
• Underpins prediction of hematopoietic response to recombinant human erythropoietin in cancer patients [6,8].
• Guides ESA therapy in myelodysplastic syndromes, where prolonged responses occur in a subset of patients.
• Provides the mechanistic context for the COMMANDS trial comparing luspatercept and epoetin alfa [2,3,4].
• Links erythropoietin signaling to non-hematopoietic tissues such as the retina in glaucoma.
• Enables identification of predictive biomarkers such as serum erythropoietin and transfusion burden [1,6,8].
• Supports development of next-generation erythroid maturation agents [2,3,4].
• Offers a framework for CRISPR-based causal gene discovery in erythropoiesis [5,7].
What Happens During response to erythropoietin?
Erythropoietin binding and receptor activation
In simple terms: Erythropoietin docks onto its receptor on the cell surface, switching on the cell's response machinery.
Response to erythropoietin begins when erythropoietin binds the erythropoietin receptor (EPOR) on erythroid progenitor cells, inducing receptor dimerization and activation of associated JAK2 kinase [1,5,7]. This receptor-proximal event is the first committed step in the cellular response and is required for downstream signaling [1,5,7].
JAK2/STAT5 signal transduction
In simple terms: Activated JAK2 phosphorylates STAT5, which then moves to the nucleus to turn on target genes.
Following EPOR activation, JAK2 phosphorylates STAT5, which translocates to the nucleus and drives transcription of genes supporting erythroid survival, proliferation, and differentiation [5,7]. This pathway is a canonical component of response to erythropoietin and is frequently assessed in experimental models [5,7].
Erythroid gene expression and differentiation
In simple terms: The cell switches on red-blood-cell-specific genes and matures into an erythroid cell.
Downstream of STAT5 and other transcription factors, erythroid progenitors upregulate genes required for hemoglobin synthesis, iron uptake, and membrane remodeling [1,5,7]. This transcriptional program underlies the functional erythroid response measured clinically as hemoglobin improvement or transfusion independence [1,6,8].
Survival and proliferation of erythroid progenitors
In simple terms: Erythropoietin keeps early red blood cell precursors alive and helps them multiply.
Erythropoietin signaling suppresses apoptosis and promotes cell-cycle progression in erythroid progenitors, expanding the pool of cells available for maturation [1,5,7]. This proliferative and survival response is a key determinant of hematopoietic response to recombinant human erythropoietin in patients [6,8].
Clinical response and predictive biomarkers
In simple terms: Doctors use blood tests and patient history to guess who will benefit from erythropoietin treatment.
Clinical response to erythropoietin is predicted by baseline serum erythropoietin levels, transfusion burden, and iron status [1,6,8]. In MDS, prolonged responses to recombinant human erythropoietin have been documented in a subset of patients, and the COMMANDS trial has refined response expectations with luspatercept versus epoetin alfa [2,3,4,5].
Key Genes Involved in GO:0036017 response to erythropoietin
The following genes and proteins are central to response to erythropoietin, spanning receptor signaling, transcriptional regulation, and erythroid effector functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EPOR | Erythropoietin receptor; binds erythropoietin and initiates signaling | Primary receptor for GO:0036017; target for knockout and knock-in studies [1,5,7] |
| JAK2 | Janus kinase 2; phosphorylates STAT5 downstream of EPOR | Key signaling node; point mutations inform pathway activation [5,7] |
| STAT5A | Signal transducer and activator of transcription 5A | Transcription factor mediating erythropoietin-induced gene expression [5,7] |
| STAT5B | Signal transducer and activator of transcription 5B | Paralog of STAT5A; contributes to erythroid gene regulation [5,7] |
| GATA1 | Master erythroid transcription factor | Essential for erythroid differentiation downstream of erythropoietin [1,5,7] |
| KLF1 | Kruppel-like factor 1; erythroid gene regulator | Modulates hemoglobin and membrane protein expression [1,5,7] |
| HBB | Beta-globin; hemoglobin subunit | Effector of erythroid maturation; readout of response [1,5,7] |
| HBA1 | Alpha-globin 1; hemoglobin subunit | Effector of erythroid maturation; readout of response [1,5,7] |
| TFRC | Transferrin receptor; iron uptake | Supports hemoglobin synthesis during erythropoietin response [1,5,7] |
| BCL2L1 | BCL2-like 1 (BCL-XL); anti-apoptotic | Promotes survival of erythroid progenitors [1,5,7] |
| EPAS1 | Endothelial PAS domain protein 1 (HIF-2alpha) | Regulates erythropoietin production and response [1,5,7] |
| HIF1A | Hypoxia-inducible factor 1 subunit alpha | Oxygen-sensing regulator of erythropoietin [1,5,7] |
| VHL | Von Hippel-Lindau tumor suppressor | Controls HIF degradation and erythropoietin expression [1,5,7] |
| EPO | Erythropoietin glycoprotein hormone | Ligand defining the stimulus for GO:0036017 [1,5,7] |
| CSF2RB | Colony stimulating factor 2 receptor beta common subunit | Modulates cytokine receptor signaling in erythroid cells [5,7] |
| LYN | LYN proto-oncogene, Src family tyrosine kinase | Modulates erythropoietin receptor signaling [5,7] |
| PTPN6 | Protein tyrosine phosphatase non-receptor type 6 (SHP-1) | Negative regulator of erythropoietin signaling [5,7] |
| SOCS3 | Suppressor of cytokine signaling 3 | Feedback inhibitor of JAK/STAT pathway [5,7] |
How Is response to erythropoietin Regulated?
Response to erythropoietin is tightly regulated at multiple levels. Receptor-proximal signaling is controlled by phosphatases such as PTPN6 (SHP-1) and SOCS proteins that attenuate JAK2/STAT5 activity [5,7]. Transcriptional output is modulated by erythroid transcription factors including GATA1 and KLF1, which coordinate hemoglobin synthesis and membrane remodeling [1,5,7]. Systemically, erythropoietin production is regulated by oxygen sensing through HIF1A, EPAS1, and VHL [1,5,7]. Clinically, response is influenced by baseline serum erythropoietin, transfusion burden, and iron status, which are used to predict benefit from ESA therapy [1,6,8]. The COMMANDS trial further informs how response expectations are shaped by alternative agents such as luspatercept [2,3,4].
response to erythropoietin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EPOR | Anemia, MDS, erythropoietin response | EPOR knockout and knock-in cell models [1,5,7] |
| JAK2 | Myeloproliferative neoplasms, MDS | JAK2 point mutation knock-in [5,7] |
| STAT5A | Erythroid differentiation defects | STAT5A knockout and overexpression [5,7] |
| GATA1 | Diamond-Blackfan anemia-like phenotypes | GATA1 knockout and rescue [1,5,7] |
| HBB | Beta-thalassemia, sickle cell disease | HBB point mutation and knock-in [1,5,7] |
Anemia of cancer and chronic disease
Impaired or insufficient response to erythropoietin contributes to anemia in cancer patients, where recombinant human erythropoietin is used to stimulate erythropoiesis [1,6,8]. Predicting which patients will respond relies on baseline serum erythropoietin, transfusion burden, and iron status [1,6,8]. Optimizing response is critical to avoid unnecessary treatment and to improve outcomes [1,6,8].
Myelodysplastic syndromes
In lower-risk MDS, response to erythropoietin is a key therapeutic endpoint, and prolonged responses to recombinant human erythropoietin have been observed in a subset of patients. The COMMANDS trial demonstrated that luspatercept can achieve transfusion independence more effectively than epoetin alfa in ESA-naive, transfusion-dependent patients [2,3,4]. These findings refine how response to erythropoietin is defined and measured in MDS [2,3,4].
Glaucoma and non-hematopoietic contexts
Erythropoietin signaling has been studied in glaucoma, where it may exert neuroprotective effects beyond erythropoiesis. This expands the biological scope of GO:0036017 to include retinal and neuronal responses to erythropoietin.
From response to erythropoietin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does EPOR loss abolish erythropoietin response? | EPOR knockout cell line [1,5,7] |
| Does a JAK2 mutation alter STAT5 activation? | JAK2 point mutation knock-in [5,7] |
| Can a tagged EPOR track receptor trafficking? | Tagged knock-in of EPOR [5,7] |
| Does GATA1 overexpression enhance erythroid differentiation? | GATA1 overexpression cell model [1,5,7] |
| Which genes mediate erythropoietin-induced survival? | CRISPR library screening [5,7] |
| Does luspatercept modulate erythropoietin response genes? | Overexpression and knockout models [2,3,4] |
How to Study the response to erythropoietin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify erythropoietin-induced transcriptional programs [1,5,7] |
| Phospho-Western blot | JAK2/STAT5 phosphorylation | Confirm receptor-proximal signaling [5,7] |
| Flow cytometry | Erythroid surface markers | Quantify differentiation after erythropoietin [1,5,7] |
| Colony-forming assay | Erythroid progenitor expansion | Assess functional response [1,5,7] |
| ELISA | Serum erythropoietin levels | Predict clinical response [1,6,8] |
| CRISPR screening | Gene essentiality for response | Discover novel regulators [5,7] |
| Proteomics | Protein abundance and modifications | Map signaling networks [5,7] |
| Imaging | Receptor localization and trafficking | Study EPOR dynamics [5,7] |
Transcriptomic profiling
RNA-seq after erythropoietin stimulation identifies genes and pathways that change during response to erythropoietin [1,5,7]. This approach can reveal erythroid differentiation markers and STAT5 target genes [5,7].
Phospho-signaling assays
Western blot and flow cytometry for phosphorylated JAK2 and STAT5 measure receptor-proximal signaling in response to erythropoietin [5,7]. These assays are used to confirm pathway activation or inhibition in CRISPR models [5,7].
Erythroid differentiation assays
Colony-forming unit assays and hemoglobin staining quantify functional erythroid maturation after erythropoietin treatment [1,5,7]. These readouts connect molecular changes to cellular outcomes [1,5,7].
Clinical response prediction
Serum erythropoietin levels, transfusion burden, and iron status are used to predict hematopoietic response to recombinant human erythropoietin [1,6,8]. These parameters inform patient selection for ESA therapy [1,6,8].
How CRISPR Can Be Used to Study GO:0036017 response to erythropoietin
Knockout
CRISPR knockout of EPOR, JAK2, or STAT5A abolishes or reduces response to erythropoietin, providing causal evidence for their roles [1,5,7]. Knockout models are used to validate candidate genes from screening studies [5,7].
Point Mutation
Point mutations in JAK2 or EPOR can mimic activating or loss-of-function alleles, revealing how specific residues control erythropoietin signaling [5,7]. These models help dissect pathway specificity and drug sensitivity [5,7].
Knock-in
Knock-in of tagged EPOR or reporter alleles enables tracking of receptor trafficking and transcriptional responses to erythropoietin [5,7]. Knock-in of disease-associated variants links genotype to response phenotypes [1,5,7].
Overexpression
Overexpression of GATA1, KLF1, or anti-apoptotic factors can enhance or perturb erythropoietin response, helping identify sufficiency relationships [1,5,7]. Overexpression models are also used to test resistance mechanisms [5,7].
How EDITGENE Supports response to erythropoietin Research
Researchers studying response to erythropoietin-related genes often need to determine whether a candidate gene is causally involved in erythropoietin signaling, erythroid differentiation, or clinical response. EDITGENE provides CRISPR-based cell model services that enable precise, reproducible interrogation of GO:0036017 mechanisms.
Contact EDITGENE today to design your custom CRISPR model for response to erythropoietin research.
Frequently Asked Questions About response to erythropoietin
What is GO:0036017 response to erythropoietin?
GO:0036017 is a biological process term describing any change in cell or organism state or activity resulting from an erythropoietin stimulus, a glycoprotein hormone that controls erythropoiesis.
What genes are involved in response to erythropoietin?
Key genes include EPOR, JAK2, STAT5A, STAT5B, GATA1, KLF1, HBB, HBA1, TFRC, and BCL2L1, among others [1,5,7].
How is response to erythropoietin measured clinically?
It is assessed by hemoglobin improvement, transfusion independence, and erythroid progenitor expansion, with prediction based on serum erythropoietin, transfusion burden, and iron status [1,6,8].
Why do some patients not respond to erythropoietin?
Non-response can result from insufficient erythropoietin receptor signaling, high baseline serum erythropoietin, heavy transfusion burden, or alternative disease mechanisms [1,6,8].
What did the COMMANDS trial show about erythropoietin response?
The COMMANDS trial compared luspatercept with epoetin alfa in ESA-naive, transfusion-dependent lower-risk MDS and showed improved transfusion independence with luspatercept [2,3,4].
Is erythropoietin involved in diseases outside anemia?
Yes, erythropoietin signaling has been studied in glaucoma, where it may have neuroprotective effects.
How can CRISPR help study response to erythropoietin?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes in erythropoietin signaling and erythroid differentiation [1,5,7].
What signaling pathways mediate response to erythropoietin?
The JAK2/STAT5 pathway is central, with additional contributions from MAPK and PI3K/AKT pathways [5,7].
Can response to erythropoietin be predicted before treatment?
Yes, baseline serum erythropoietin levels, transfusion burden, and iron status are used to predict hematopoietic response to recombinant human erythropoietin [1,6,8].
What cell models are used to study response to erythropoietin?
Erythroid progenitor cell lines, knockout models, knock-in reporters, and overexpression systems are commonly used [1,5,7].
Conclusion
GO:0036017 (response to erythropoietin) is a clinically and biologically central process that governs erythroid proliferation, survival, and differentiation. Its dysregulation underlies anemia in cancer and MDS, and its modulation is the basis of ESA therapy [1,6,8]. The COMMANDS trial has reshaped treatment expectations by comparing luspatercept with epoetin alfa in lower-risk MDS [2,3,4]. CRISPR-based models are essential for dissecting the causal genes and pathways within response to erythropoietin. EDITGENE provides comprehensive knockout, point mutation, knock-in, overexpression, and screening services to accelerate discovery in this field [1,5,7].
References
- 1. Beguin Y. 1998. Prediction of response to optimize outcome of treatment with erythropoietin.. Semin Oncol 25(3 Suppl 7):27-34 PMID: 9671327
- 2. Della Porta MG et al.. 2024. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.. Lancet Haematol 11(9):e646-e658 PMID: 39038479
- 3. Platzbecker U et al.. 2023. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.. Lancet 402(10399):373-385 PMID: 37311468
- 4. Garcia-Manero G et al.. 2025. Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.. Adv Ther 42(7):3576-3589 PMID: 40377899
- 5. Moura ATG et al.. 2019. Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil.. Clinics (Sao Paulo) 74:e771 PMID: 31508719
- 6. Adamson JW et al.. 1999. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.. Oncology 56(1):46-53 PMID: 9885377
- 7. Lai YF et al.. 2023. Erythropoietin in Glaucoma: From Mechanism to Therapy.. Int J Mol Sci 24(3) PMID: 36769310
- 8. Henry DH 3rd et al.. 1996. Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients.. Semin Hematol 33(1 Suppl 1):2-5 PMID: 8714608
